Sigma® Life Science to Supply Oligonucleotides to Research Councils UK
News Sep 20, 2010
Sigma® Life Science, a division of Sigma-Aldrich® Corporation and a European manufacturer of oligonucleotides, has signed a three-year contract with Research Councils UK (RCUK) Shared Services Centre Limited to be a preferred supplier for synthetic oligonucleotides.
With more than 20 years of experience in oligonucleotide synthesis, Sigma Life Science offers a broad commercially available range of high quality oligonucleotide modifications, purifications, synthesis scales and qPCR probes.
Michael Harris, Managing Director of Europe, Middle East, Africa regions for Sigma-Aldrich, commented: “Sigma Life Science has been a preferred oligonucleotide supplier to the Medical Research Council (one of the UK’s seven Research Councils) for over four years, and we are delighted that the quality of our products and service has resulted in the expansion of this contract. This new agreement is expected to enable additional RCUK researchers to access Sigma’s products, as well as allow Sigma Life Science to consolidate its relationship with RCUK.”
Sigma Life Science provides a wide range of other molecular biology reagents, including nucleic acid amplification and purification reagents, RNAi products (including shRNA, siRNA and the innovative ZFN technology) and more than 38,000 antibodies.
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
RNA Molecules Lives Are 10 Times Shorter Than Previously ThoughtNews
A research group at the Biozentrum of the University of Basel has developed a new method to measure the half-life of RNA molecules.READ MORE
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018